Ultra-Short Acting Opioid Analgesic
Pregnancy: Use with caution at delivery — rapid neonatal clearance expected; ensure resuscitation available
Remifentanil
Brand names: Ultiva
Adult dose
Dose: 0.05-2 micrograms/kg/min IV infusion (TIVA/intraoperative); 0.025-0.2 micrograms/kg/min (sedation)
Route: Intravenous infusion
Frequency: Continuous infusion
Max: Titrated to effect; bolus doses: 0.25-1 microgram/kg over 30 seconds
Must be used with appropriate ventilatory support. Dilute to 20-50 micrograms/mL for infusion. STOP at end of surgery — no residual analgesia; ensure adequate long-acting analgesia established before stopping
Paediatric dose
Dose: 0.05-1 microgram/kg/min IV infusion micrograms/min/kg
Route: IV infusion
Frequency: Continuous intraoperative
Max: Titrated to effect
Child 1 month to 11 years: 0.05-0.3 micrograms/kg/min. Adolescent: same as adult. Neonates: specialist use only
Dose adjustments
Renal
No dose adjustment — ester hydrolysis by plasma esterases, not organ-dependent
Hepatic
No dose adjustment — not hepatically metabolised
Paediatric weight-based calculator
Child 1 month to 11 years: 0.05-0.3 micrograms/kg/min. Adolescent: same as adult. Neonates: specialist use only
Clinical pearls
- Unique pharmacokinetics: metabolised by non-specific plasma and tissue esterases — context-sensitive half-time remains approximately 3-4 minutes regardless of infusion duration; no accumulation
- Post-operative analgesia MUST be planned before stopping remifentanil — its offset is so rapid that patients can wake in severe pain; multi-modal analgesia (paracetamol, NSAID, morphine) should be given intraoperatively
- Opioid-induced hyperalgesia (OIH): paradoxical increase in pain sensitivity after prolonged remifentanil — ketamine co-infusion (0.1-0.5 mg/kg/hr) partially prevents this
- Antidote: naloxone (as for all opioids) — but given remifentanil's ultra-short action, maintaining ventilation is usually sufficient
- Ideal for procedures requiring fine titration of analgesia (neurosurgery, awake craniotomy, laparoscopic surgery) and where rapid emergence is needed
Contraindications
- Use without facilities for immediate intubation and ventilation
- Epidural or intrathecal administration
Side effects
- Respiratory depression (profound, rapid)
- Muscle rigidity (chest wall — high doses)
- Bradycardia and hypotension
- Opioid-induced hyperalgesia (OIH — prolonged or high-dose use causes paradoxical pain sensitisation post-op)
Interactions
- Anaesthetic agents (significant synergy — propofol, volatiles; reduce requirements by 30-50%)
- Other opioids (additive respiratory depression)
Monitoring
- Continuous SpO2 and end-tidal CO2
- Blood pressure
- Heart rate
- Level of consciousness
Reference: BNFc; BNF 90; Ultiva SPC; Minto et al. (1997) PK model; AAGBI Guidelines. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Morphine Milligram Equivalents (MME) Calculator · Pain / Opioids
- Opioid Conversion / Equianalgesic Guide · Pain Management
- Numeric Rating Scale (NRS) Pain Assessment and Management · Pain Management
- Finnegan Neonatal Abstinence Scoring Tool (FNAST) · Neonatal Abstinence Syndrome
- Modified Finnegan Neonatal Abstinence Score (NAS) · Neonatal
- Cervical Cerclage Criteria (Short Cervix / Preterm Risk) · Preterm Labour
Pathways
- Major Trauma — Primary Survey (ATLS) · ATLS 10th Edition; JRCALC; NICE NG39
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Lower Gastrointestinal Bleed · NICE; BSG; ACPGBI — Commissioning Guide
- Acute Pancreatitis · NICE; IAP/APA; ACPGBI — CG104
- Faecal Peritonitis · ASGBI; RCS — Best Practice
- Acute Compartment Syndrome · BAPRAS; BOA; RCS — Best Practice